{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:44:33Z","timestamp":1767707073927},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s11906-004-0058-9","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T19:27:58Z","timestamp":1180034878000},"page":"383-392","source":"Crossref","is-referenced-by-count":14,"title":["Antiproteinuric effect of RAS blockade: New mechanisms"],"prefix":"10.1007","volume":"6","author":[{"given":"Markus","family":"Lassila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Jandeleit-Dahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"58_CR1","first-page":"354","volume":"45","author":"P Rossing","year":"1998","unstructured":"Rossing P: Promotion, prediction, and prevention of progression in diabetic nephropathy. Dan Med Bull 1998, 45:354\u2013369.","journal-title":"Dan Med Bull"},{"key":"58_CR2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754\u2013762.","journal-title":"Ann Intern Med"},{"key":"58_CR3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","volume":"63","author":"WF Keane","year":"2003","unstructured":"Keane WF, Brenner BM, de Zeeuw D, et al.: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003, 63:1499\u20131507.","journal-title":"Kidney Int"},{"key":"58_CR4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/bmj.294.6588.1651","volume":"294","author":"K Borch-Johnsen","year":"1987","unstructured":"Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987, 294:1651\u20131654.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"58_CR5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/diab.44.11.1303","volume":"44","author":"MA Gall","year":"1995","unstructured":"Gall MA, Borch-Johnsen K, Hougaard P, et al.: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995, 44:1303\u20131309.","journal-title":"Diabetes"},{"key":"58_CR6","first-page":"S174","volume":"45","author":"AJ Apperloo","year":"1994","unstructured":"Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994, 45:S174-S178.","journal-title":"Kidney Int Suppl"},{"key":"58_CR7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1523-1755.62.s82.13.x","volume":"82","author":"S Shahinfar","year":"2002","unstructured":"Shahinfar S, Dickson TZ, Ahmed T, et al.: Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. Kidney Int Suppl 2002, 82:64\u201367.","journal-title":"Kidney Int Suppl"},{"key":"58_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semnephrol.2003.11.003","volume":"24","author":"HH Parving","year":"2004","unstructured":"Parving HH, Andersen S, Jacobsen P, et al.: Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004, 24:147\u2013157. Extensive review summarizing the recent evidence for the effects of angiotensin receptor blockers in diabetic nephropathy, with a particular focus on effects on proteinuria and translation into renal and cardiovascular end points.","journal-title":"Semin Nephrol"},{"key":"58_CR9","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"Zeeuw D De","year":"2004","unstructured":"De Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309\u20132320. This post-hoc analysis emphasizes in detail the importance of baseline proteinuria and the effect of RAS blockade on proteinuria as a predictor of long-term renal protection and outcome.","journal-title":"Kidney Int"},{"key":"58_CR10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1046\/j.1523-1755.1999.00721.x","volume":"56","author":"RE Gilbert","year":"1999","unstructured":"Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999, 56:1627\u20131637.","journal-title":"Kidney Int"},{"key":"58_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.semnephrol.2003.11.004","volume":"24","author":"R Abdi","year":"2004","unstructured":"Abdi R, Brenner BM: Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning? Semin Nephrol 2004, 24:141\u2013146.","journal-title":"Semin Nephrol"},{"key":"58_CR12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2337\/diabetes.52.4.1023","volume":"52","author":"S Doublier","year":"2003","unstructured":"Doublier S, Salvidio G, Lupia E, et al.: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003, 52:1023\u20131030. Some of the first evidence for nephrin depletion in human diabetic nephropathy and the association with angiotensin II.","journal-title":"Diabetes"},{"key":"58_CR13","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0002-9440(10)63552-3","volume":"163","author":"M Ruperez","year":"2003","unstructured":"Ruperez M, Ruiz-Ortega M, Esteban V, et al.: Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003, 163:1937\u20131947.","journal-title":"Am J Pathol"},{"key":"58_CR14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/00004872-200107000-00009","volume":"19","author":"RM Touyz","year":"2001","unstructured":"Touyz RM, Schiffrin EL: Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001, 19:1245\u20131254.","journal-title":"J Hypertens"},{"key":"58_CR15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","volume":"134","author":"Group AIiDNT","year":"2001","unstructured":"Group AIiDNT: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensinconverting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001, 134:370\u2013379.","journal-title":"Ann Intern Med"},{"key":"58_CR16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860.","journal-title":"N Engl J Med"},{"key":"58_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","volume":"156","author":"M Ravid","year":"1996","unstructured":"Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996, 156:286\u2013289.","journal-title":"Arch Intern Med"},{"key":"58_CR18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861\u2013869.","journal-title":"N Engl J Med"},{"key":"58_CR19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870\u2013878.","journal-title":"N Engl J Med"},{"key":"58_CR20","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456\u20131462.","journal-title":"N Engl J Med"},{"key":"58_CR21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ndt\/18.2.293","volume":"18","author":"S Andersen","year":"2003","unstructured":"Andersen S, Jacobsen P, Tarnow L, et al.: Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003, 18:293\u2013297.","journal-title":"Nephrol Dial Transplant"},{"key":"58_CR22","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/S0149-2918(03)90091-9","volume":"25","author":"LM Ruilope","year":"2003","unstructured":"Ruilope LM, Segura J: Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 2003, 25:3044\u20133064.","journal-title":"Clin Ther"},{"key":"58_CR23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0272-6386(05)80003-4","volume":"37","author":"G Jerums","year":"2001","unstructured":"Jerums G, Allen TJ, Campbell DJ, et al.: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001, 37:890\u2013899.","journal-title":"Am J Kidney Dis"},{"key":"58_CR24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1523-1755.2000.00879.x","volume":"57","author":"JC Chan","year":"2000","unstructured":"Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590\u2013600.","journal-title":"Kidney Int"},{"key":"58_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","volume":"58","author":"Y Lacourciere","year":"2000","unstructured":"Lacourciere Y, Belanger A, Godin C, et al.: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000, 58:762\u2013769.","journal-title":"Kidney Int"},{"key":"58_CR26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00041552-200405000-00006","volume":"13","author":"J Ly","year":"2004","unstructured":"Ly J, Alexander M, Quaggin SE: A podocentric view of nephrology. Curr Opin Nephrol Hypertens 2004, 13:299\u2013305. This review summarizes in detail the role of the podocyte slit pore diaphragm in controlling protein leakage.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"58_CR27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/01.ASN.0000016142.29721.22","volume":"13","author":"M Rantanen","year":"2002","unstructured":"Rantanen M, Palmen T, Patari A, et al.: Nephrin TRAP mice lack slit diaphragms and show fibrotic glomeruli and cystic tubular lesions. J Am Soc Nephrol 2002, 13:1586\u20131594.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1126\/science.286.5438.312","volume":"286","author":"NY Shih","year":"1999","unstructured":"Shih NY, Li J, Karpitskii V, et al.: Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999, 286:312\u2013315.","journal-title":"Science"},{"key":"58_CR29","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1128\/MCB.21.14.4829-4836.2001","volume":"21","author":"DB Donoviel","year":"2001","unstructured":"Donoviel DB, Freed DD, Vogel H, et al.: Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 2001, 21:4829\u20134836.","journal-title":"Mol Cell Biol"},{"key":"58_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/snep.2002.34724","volume":"22","author":"ME Cooper","year":"2002","unstructured":"Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 2002, 22:393\u2013398. Detailed review about the role of nephrin with a focus on diabetic nephropathy, with a mechanistic assessment of treatments.","journal-title":"Semin Nephrol"},{"key":"58_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/labinvest.3780392","volume":"82","author":"S Hoshi","year":"2002","unstructured":"Hoshi S, Shu Y, Yoshida F, et al.: Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002, 82:25\u201335.","journal-title":"Lab Invest"},{"key":"58_CR32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00125-003-1106-8","volume":"46","author":"ML Gross","year":"2003","unstructured":"Gross ML, El-Shakmak A, Szabo A, et al.: ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46:856\u2013868.","journal-title":"Diabetologia"},{"key":"58_CR33","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/j.1523-1755.2004.00636.x","volume":"65","author":"A Benigni","year":"2004","unstructured":"Benigni A, Gagliardini E, Tomasoni S, et al.: Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004, 65:2193\u20132200. One of the first reports emphasizing the redistribution of nephrin in human diabetic nephropathy.","journal-title":"Kidney Int"},{"key":"58_CR34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ndt\/gfg545","volume":"19","author":"M Toyoda","year":"2004","unstructured":"Toyoda M, Suzuki D, Umezono T, et al.: Expression of human nephrin mRNA in diabetic nephropathy. Nephrol Dial Transplant 2004, 19:380\u2013385.","journal-title":"Nephrol Dial Transplant"},{"key":"58_CR35","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/01.ASN.0000078803.53165.C9","volume":"14","author":"K Koop","year":"2003","unstructured":"Koop K, Eikmans M, Baelde HJ, et al.: Expression of podocyteassociated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003, 14:2063\u20132071.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR36","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/17.7.1327","volume":"17","author":"DJ Kelly","year":"2002","unstructured":"Kelly DJ, Aaltonen P, Cox AJ, et al.: Expression of the slitdiaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002, 17:1327\u20131332.","journal-title":"Nephrol Dial Transplant"},{"key":"58_CR37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00004872-200301000-00031","volume":"21","author":"BJ Davis","year":"2003","unstructured":"Davis BJ, Cao Z, de Gasparo M, et al.: Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003, 21:209\u2013216.","journal-title":"J Hypertens"},{"key":"58_CR38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","volume":"44","author":"F Bonnet","year":"2001","unstructured":"Bonnet F, Cooper ME, Kawachi H, et al.: Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001, 44:874\u2013847. One of the first reports showing that RAS blockade restores nephrin depletion in diabetic nephropathy.","journal-title":"Diabetologia"},{"key":"58_CR39","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/labinvest.3780332","volume":"81","author":"P Aaltonen","year":"2001","unstructured":"Aaltonen P, Luimula P, Astrom E, et al.: Changes in the expression of nephrin gene and protein in experimental diabetic nephropathy. Lab Invest 2001, 81:1185\u20131190. Original contribution to the findings of nephrin gene and protein depletion and redistribution in experimental diabetic nephropathy.","journal-title":"Lab Invest"},{"key":"58_CR40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00004872-200205000-00034","volume":"20","author":"JM Forbes","year":"2002","unstructured":"Forbes JM, Bonnet F, Russo LM, et al.: Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 2002, 20:985\u2013992.","journal-title":"J Hypertens"},{"key":"58_CR41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s001250100561","volume":"44","author":"SA Mifsud","year":"2001","unstructured":"Mifsud SA, Allen TJ, Bertram JF, et al.: Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001, 44:878\u2013882.","journal-title":"Diabetologia"},{"key":"58_CR42","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s00125-002-0946-y","volume":"45","author":"RG Langham","year":"2002","unstructured":"Langham RG, Kelly DJ, Cox AJ, et al.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002, 45:1572\u20131576.","journal-title":"Diabetologia"},{"key":"58_CR43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/emm.2004.9","volume":"36","author":"EY Lee","year":"2004","unstructured":"Lee EY, Shim MS, Kim MJ, et al.: Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004, 36:65\u201370. Original report showing that AT1 receptor antagonisms reduces podocyte VEGF expression in diabetic nephropathy.","journal-title":"Exp Mol Med"},{"key":"58_CR44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/ndt\/gfg509","volume":"19","author":"RG Langham","year":"2004","unstructured":"Langham RG, Kelly DJ, Cox AJ, et al.: Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant 2004, 19:262\u2013263.","journal-title":"Nephrol Dial Transplant"},{"key":"58_CR45","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.ASN.0000019409.17099.33","volume":"13","author":"Z Cao","year":"2002","unstructured":"Cao Z, Bonnet F, Candido R, et al.: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002, 13:1773\u20131787.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR46","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1097\/01.ASN.0000077413.41276.17","volume":"14","author":"JM Forbes","year":"2003","unstructured":"Forbes JM, Cooper ME, Oldfield MD, Thomas MC: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR47","doi-asserted-by":"crossref","first-page":"11704","DOI":"10.1073\/pnas.91.24.11704","volume":"91","author":"H Vlassara","year":"1994","unstructured":"Vlassara H, Striker LJ, Teichberg S, et al.: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994, 91:11704\u201311708.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"58_CR48","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1096\/fj.02-1102fje","volume":"17","author":"JM Forbes","year":"2003","unstructured":"Forbes JM, Thallas V, Thomas MC, et al.: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003, 17:1762\u20131764.","journal-title":"FASEB J"},{"key":"58_CR49","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1097\/01.ASN.0000032418.67267.F2","volume":"13","author":"T Miyata","year":"2002","unstructured":"Miyata T, van Ypersele de Strihou C, Ueda Y, et al.: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002, 13:2478\u20132487. Original report describing reduced AGE formation with RAS blockade in vitro.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR50","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","volume":"51","author":"JM Forbes","year":"2002","unstructured":"Forbes JM, Cooper ME, Thallas V, et al.: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002, 51:3274\u20133282. First paper to demonstrate inhibition of AGE accumulation with ACE inhibition in vivo in a model of diabetic nephropathy.","journal-title":"Diabetes"},{"key":"58_CR51","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/01.ASN.0000062961.76776.C1","volume":"14","author":"M Nangaku","year":"2003","unstructured":"Nangaku M, Miyata T, Sada T, et al.: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003, 14:1212\u20131222.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787\u2013790.","journal-title":"Nature"},{"key":"58_CR53","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","volume":"48","author":"ME Cooper","year":"1999","unstructured":"Cooper ME, Vranes D, Youssef S, et al.: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999, 48:2229\u20132239. Original description of increased VEGF and its receptor expression in experimental diabetes emphasizing a pivotal role of VEGF for proteinuria.","journal-title":"Diabetes"},{"key":"58_CR54","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, et al.: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111:707\u2013716.","journal-title":"J Clin Invest"},{"key":"58_CR55","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","volume":"12","author":"AS Vriese de","year":"2001","unstructured":"de Vriese AS, Tilton RG, Elger M, et al.: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001, 12:993\u20131000.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR56","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2337\/diabetes.51.10.3090","volume":"51","author":"A Flyvbjerg","year":"2002","unstructured":"Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al.: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002, 51:3090\u20133094. This paper shows that antagonism of VEGF with a neutralizing antibody ameliorated proteinuria and the progression of nephropathy in diabetes.","journal-title":"Diabetes"},{"key":"58_CR57","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s001250051515","volume":"43","author":"A Flyvbjerg","year":"2000","unstructured":"Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000, 43:1205\u20131223.","journal-title":"Diabetologia"},{"key":"58_CR58","first-page":"S104","volume":"77","author":"DR Cha","year":"2000","unstructured":"Cha DR, Kim NH, Yoon JW, et al.: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000, 77:S104-S112.","journal-title":"Kidney Int Suppl"},{"key":"58_CR59","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1046\/j.1523-1755.2000.07504.x","volume":"75","author":"P Hovind","year":"2000","unstructured":"Hovind P, Tarnow L, Oestergaard PB, Parving HH: Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000, 75:S56-S61.","journal-title":"Kidney Int Suppl"},{"key":"58_CR60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000113628.94574.0f","volume":"43","author":"X Zhang","year":"2004","unstructured":"Zhang X, Lassila M, Cooper ME, Cao Z: Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004, 43:276\u2013281.","journal-title":"Hypertension"},{"key":"58_CR61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.HYP.25.5.913","volume":"25","author":"B Williams","year":"1995","unstructured":"Williams B, Baker AQ, Gallacher B, Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995, 25:913\u2013917.","journal-title":"Hypertension"},{"key":"58_CR62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF03402169","volume":"8","author":"K Koga","year":"2002","unstructured":"Koga K, Yamagishi S, Takeuchi M, et al.: CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 2002, 8:591\u2013599.","journal-title":"Mol Med"},{"key":"58_CR63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2001-0039","volume":"23","author":"JL Evans","year":"2002","unstructured":"Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599\u2013622.","journal-title":"Endocr Rev"},{"key":"58_CR64","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","volume":"162","author":"TM Wendt","year":"2003","unstructured":"Wendt TM, Tanji N, Guo J, et al.: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003, 162:1123\u20131137.","journal-title":"Am J Pathol"},{"key":"58_CR65","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1073\/pnas.120055097","volume":"97","author":"FN Ziyadeh","year":"2000","unstructured":"Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db\/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015\u20138020.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"58_CR66","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/S0270-9295(03)00132-3","volume":"23","author":"S Chen","year":"2003","unstructured":"Chen S, Jim B, Ziyadeh FN: Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003, 23:532\u2013543.","journal-title":"Semin Nephrol"},{"key":"58_CR67","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1172\/JCI200112367","volume":"108","author":"M Schiffer","year":"2001","unstructured":"Schiffer M, Bitzer M, Roberts IS, et al.: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807\u2013816.","journal-title":"J Clin Invest"},{"key":"58_CR68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1523-1755.2004.00362.x","volume":"65","author":"RV Durvasula","year":"2004","unstructured":"Durvasula RV, Petermann AT, Hiromura K, et al.: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30\u201339.","journal-title":"Kidney Int"},{"key":"58_CR69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000074845","volume":"95","author":"S Mifsud","year":"2003","unstructured":"Mifsud S, Kelly DJ, Qi W, et al.: Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003, 95:83\u201391.","journal-title":"Nephron Physiol"},{"key":"58_CR70","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0272-6386(99)70037-5","volume":"34","author":"K Sharma","year":"1999","unstructured":"Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factorbeta1 correlates with long-term renoprotection in insulindependent diabetic patients. Am J Kidney Dis 1999, 34:818\u2013823.","journal-title":"Am J Kidney Dis"},{"key":"58_CR71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/ajkd.2000.19078","volume":"36","author":"GT Shin","year":"2000","unstructured":"Shin GT, Kim SJ, Ma KA, et al.: ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis 2000, 36:894\u2013902.","journal-title":"Am J Kidney Dis"},{"key":"58_CR72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/01.HYP.36.4.561","volume":"36","author":"Z Cao","year":"2000","unstructured":"Cao Z, Cooper ME, Wu LL, et al.: Blockade of the reninangiotensin and endothelin systems on progressive renal injury. Hypertension 2000, 36:561\u2013568.","journal-title":"Hypertension"},{"key":"58_CR73","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.2337\/diacare.25.12.2320","volume":"25","author":"N Chaturvedi","year":"2002","unstructured":"Chaturvedi N, Schalkwijk CG, Abrahamian H, et al.: Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2002, 25:2320\u20132327.","journal-title":"Diabetes Care"},{"key":"58_CR74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1681\/ASN.V11125","volume":"11","author":"BL Riser","year":"2000","unstructured":"Riser BL, Denichilo M, Cortes P, et al.: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000, 11:25\u201338.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR75","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/diacare.27.5.1164","volume":"27","author":"P Roestenberg","year":"2004","unstructured":"Roestenberg P, van Nieuwenhoven FA, Wieten L, et al.: Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004, 27:1164\u20131170.","journal-title":"Diabetes Care"},{"key":"58_CR76","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/diacare.26.9.2632","volume":"26","author":"RE Gilbert","year":"2003","unstructured":"Gilbert RE, Akdeniz A, Weitz S, et al.: Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003, 26:2632\u20132636.","journal-title":"Diabetes Care"},{"key":"58_CR77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1523-1755.2003.00130.x","volume":"64","author":"BL Riser","year":"2003","unstructured":"Riser BL, Cortes P, DeNichilo M, et al.: Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 2003, 64:451\u2013458.","journal-title":"Kidney Int"},{"key":"58_CR78","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-004-1423-6","volume":"47","author":"SM Twigg","year":"2004","unstructured":"Twigg SM, Cooper ME: The time to target connective tissue growth factor in diabetic complications is nigh. Diabetologia 2004, 47:965\u2013968.","journal-title":"Diabetologia"},{"key":"58_CR79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00041552-200111000-00001","volume":"10","author":"OV Sakharova","year":"2001","unstructured":"Sakharova OV, Taal MW, Brenner BM: Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens 2001, 10:727\u2013738.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"58_CR80","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1074\/jbc.274.9.5830","volume":"274","author":"M Murphy","year":"1999","unstructured":"Murphy M, Godson C, Cannon S, et al.: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999, 274:5830\u20135834.","journal-title":"J Biol Chem"},{"key":"58_CR81","first-page":"67","volume":"24","author":"BC Liu","year":"2003","unstructured":"Liu BC, Chen Q, Luo DD, et al.: Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003, 24:67\u201373.","journal-title":"Acta Pharmacol Sin"},{"key":"58_CR82","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1097\/01.ASN.0000077410.66390.0F","volume":"14","author":"HB Lee","year":"2003","unstructured":"Lee HB, Yu MR, Yang Y, et al.: Reactive oxygen speciesregulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S241-S245. This paper emphasizes the pivotal role of oxidative stress and related signaling pathways for the development and progression of diabetic nephropathy.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR83","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1523-1755.2001.059002415.x","volume":"59","author":"C Guijarro","year":"2001","unstructured":"Guijarro C, Egido J: Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001, 59:415\u2013424.","journal-title":"Kidney Int"},{"key":"58_CR84","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1038\/sj.onc.1203174","volume":"18","author":"F Mercurio","year":"1999","unstructured":"Mercurio F, Manning AM: NF-kappaB as a primary regulator of the stress response. Oncogene 1999, 18:6163\u20136171.","journal-title":"Oncogene"},{"key":"58_CR85","doi-asserted-by":"crossref","unstructured":"Mezzano S, Droguett A, Burgos ME, et al.: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003, S64\u2013S70.","DOI":"10.1046\/j.1523-1755.64.s86.12.x"},{"key":"58_CR86","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1046\/j.1523-1755.64.s86.7.x","volume":"86","author":"V Esteban","year":"2003","unstructured":"Esteban V, Ruperez M, Vita JR, et al.: Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl 2003, 86:S33-S38. This report links both the angiotensin AT1 and AT2 receptors with overexpression of the transcription factor NF kappa B in diabetes.","journal-title":"Kidney Int Suppl"},{"key":"58_CR87","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0272-6386(03)00741-8","volume":"42","author":"KR Tuttle","year":"2003","unstructured":"Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003, 42:456\u2013465.","journal-title":"Am J Kidney Dis"},{"key":"58_CR88","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.RES.81.3.363","volume":"81","author":"A Hempel","year":"1997","unstructured":"Hempel A, Maasch C, Heintze U, et al.: High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997, 81:363\u2013371.","journal-title":"Circ Res"},{"key":"58_CR89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.272.5262.728","volume":"272","author":"H Ishii","year":"1996","unstructured":"Ishii H, Jirousek MR, Koya D, et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728\u2013731. Original report demonstrating the pivotal role of PKC beta for vascular dysfunction in diabetes.","journal-title":"Science"},{"key":"58_CR90","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diabetes.52.2.512","volume":"52","author":"DJ Kelly","year":"2003","unstructured":"Kelly DJ, Zhang Y, Hepper C, et al.: Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003, 52:512\u2013518.","journal-title":"Diabetes"},{"key":"58_CR91","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1096\/fasebj.14.3.439","volume":"14","author":"D Koya","year":"2000","unstructured":"Koya D, Haneda M, Nakagawa H, et al.: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db\/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439\u2013447. This paper demonstrates the importance of PKC beta in a model of type 2 diabetic nephropathy.","journal-title":"FASEB J"},{"key":"58_CR92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8227(02)00194-8","volume":"59","author":"K Ikehara","year":"2003","unstructured":"Ikehara K, Tada H, Kuboki K, Inokuchi T: Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels. Diabetes Res Clin Pract 2003, 59:25\u201330.","journal-title":"Diabetes Res Clin Pract"},{"key":"58_CR93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000066789","volume":"25","author":"IL Pfaff","year":"2002","unstructured":"Pfaff IL, Vallon V: Protein kinase C beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ACE inhibitor lisinopril. Kidney Blood Press Res 2002, 25:329\u2013340.","journal-title":"Kidney Blood Press Res"},{"key":"58_CR94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/diabetes.49.1.87","volume":"49","author":"TM Osicka","year":"2000","unstructured":"Osicka TM, Yu Y, Panagiotopoulos S, et al.: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000, 49:87\u201393.","journal-title":"Diabetes"},{"key":"58_CR95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1681\/ASN.V131108","volume":"13","author":"MF Melhem","year":"2002","unstructured":"Melhem MF, Craven PA, Liachenko J, DeRubertis FR: Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002, 13:108\u2013116.","journal-title":"J Am Soc Nephrol"},{"key":"58_CR96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/01.HYP.0000104524.25807.EE","volume":"43","author":"MW Brands","year":"2004","unstructured":"Brands MW, Bell TD, Gibson B: Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension 2004, 43:57\u201363.","journal-title":"Hypertension"},{"key":"58_CR97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1523-1755.1998.00068.x","volume":"54","author":"EA Jaimes","year":"1998","unstructured":"Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998, 54:775\u2013784.","journal-title":"Kidney Int"},{"key":"58_CR98","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/hy1101.092845","volume":"38","author":"EM Cavanagh de","year":"2001","unstructured":"de Cavanagh EM, Inserra F, Toblli J, et al.: Enalapril attenuates oxidative stress in diabetic rats. Hypertension 2001, 38:1130\u20131136.","journal-title":"Hypertension"},{"key":"58_CR99","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1046\/j.1440-1681.2001.03530.x","volume":"28","author":"K Sugimoto","year":"2001","unstructured":"Sugimoto K, Tsuruoka S, Fujimura A: Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. Clin Exp Pharmacol Physiol 2001, 28:826\u2013830.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"58_CR100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1053\/ajkd.2002.32764","volume":"39","author":"LM Russo","year":"2002","unstructured":"Russo LM, Bakris GL, Comper WD: Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002, 39:899\u2013919. This review suggests an alternative mechanism for proteinuria. It is hypothesized that impaired processing of albumin by tubular cells in various disease states, such as diabetic nephropathy, may play a major role in the pathogenesis of proteinuria in diabetes.","journal-title":"Am J Kidney Dis"},{"key":"58_CR101","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004872-200302000-00035","volume":"21","author":"LM Russo","year":"2003","unstructured":"Russo LM, Brammar GC, Jerums G, et al.: The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression. J Hypertens 2003, 21:419\u2013428.","journal-title":"J Hypertens"},{"key":"58_CR102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000068528","volume":"93","author":"SP Clavant","year":"2003","unstructured":"Clavant SP, Forbes JM, Thallas V, et al.: Reversible angiotensin II-mediated albuminuria in rat kidneys is dynamically associated with cytoskeletal organization. Nephron Physiol 2003, 93:51\u201360.","journal-title":"Nephron Physiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-004-0058-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0058-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T04:49:21Z","timestamp":1628916561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-004-0058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s11906-004-0058-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}